Generex Biotechnology announces $224 000 Phase I National Institute of Health Small Business Innovative Research (SBIR) Award for Preclinical Development of a Novel HER-2/neu Peptide Vaccine for Breast Cancer. This novel vaccine stimulates the immune system to segments of HER-2/neu a dominant antigen found on certain breast cancer cells.
|
All times are GMT -7. The time now is 08:44 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021